INVEMOX Premix 100 mg/g премикс за медикаментозни фуражи за прасета INVEMOX Premix 100 mg/g premix for medicated feeding stuff f Bulgaria - Bulgaria - БАБХ (Българска агенция по безопасност на храните)

invemox premix 100 mg/g премикс за медикаментозни фуражи за прасета invemox premix 100 mg/g premix for medicated feeding stuff f

industrial veterinaria, s.a. - Амоксицилин основание (амоксициллина тригидрат) - премикс за медикаментозен фураж - 100 mg/g - прасета

KETINK 100 mg/ml инжекционен разтвор за говеда, коне и свине 100 mg/ml Bulgaria - Bulgaria - БАБХ (Българска агенция по безопасност на храните)

ketink 100 mg/ml инжекционен разтвор за говеда, коне и свине 100 mg/ml

industrial veterinaria, s.a. - Кетопрофен - инжекционен разтвор - 100 mg/ml - говеда, коне, свине

OXYSYS 200 LA 200 mg/ml Bulgaria - Bulgaria - БАБХ (Българска агенция по безопасност на храните)

oxysys 200 la 200 mg/ml

industrial veterinaria, s.a. - Окситетрациклин (като дигидрат) - инжекционен разтвор - 200 mg/ml - говеда, кози, овце, свине

ROLENOL 50 mg/ml Bulgaria - Bulgaria - БАБХ (Българска агенция по безопасност на храните)

rolenol 50 mg/ml

industrial veterinaria, s.a. - Клозантела - инжекционен разтвор - 50 mg/ml - говеда, овце

BOFLOX, 100 mg/ml инжекционен разтвор за говеда и свине 100 mg/ml Bulgaria - Bulgaria - БАБХ (Българска агенция по безопасност на храните)

boflox, 100 mg/ml инжекционен разтвор за говеда и свине 100 mg/ml

industrial veterinaria, s.a. - Марбофлоксацин - инжекционен разтвор - 100 mg/ml - говеда, свине

RHEMOX 500 mg/g powder for use in drinking water for pigs, chicken broilers, duck broilers and turkeys for meat production 500 mg/g Bulgaria - Bulgaria - БАБХ (Българска агенция по безопасност на храните)

rhemox 500 mg/g powder for use in drinking water for pigs, chicken broilers, duck broilers and turkeys for meat production 500 mg/g

industrial veterinaria, s.a. - Амоксициллина тригидрат - прах за прилагане във вода за пиене - 500 mg/g - патици, пилета, прасета, пуйки

Sitagliptin Accord Kesatuan Eropah - Bulgaria - EMA (European Medicines Agency)

sitagliptin accord

accord healthcare s.l.u. - sitagliptin hydrochloride - Захарен диабет тип 2 - Лекарства, използвани при диабет - for adult patients with type 2 diabetes mellitus, sitagliptin accord is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (ppary) agonist (i. a thiazolidinedione) when use of a ppary agonist is appropriate and when diet and exercise plus the ppary agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a ppary agonist and metformin when use of a ppary agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin accord is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

Trodelvy Kesatuan Eropah - Bulgaria - EMA (European Medicines Agency)

trodelvy

gilead sciences ireland uc - sacituzumab govitecan - breast neoplasms; triple negative breast neoplasms - Антинеопластични средства - trodelvy as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (mtnbc) who have received two or more prior systemic therapies, including at least one of them for advanced disease.

Rivaroxaban Accord Kesatuan Eropah - Bulgaria - EMA (European Medicines Agency)

rivaroxaban accord

accord healthcare s.l.u. - ривароксабан - acute coronary syndrome; coronary artery disease; peripheral arterial disease; venous thromboembolism; stroke; atrial fibrillation; pulmonary embolism - Антитромботични агенти - Предотвратяване на венозна тромбоемболия (ВТЕ) при възрастни пациенти, подложени на елективна операция за замяна на тазобедрена или колянна става. Лечение на дълбока венозна тромбоза (dvt) и тромбоэмболии белодробната артерия (ТЭЛА) и за превенция на рецидив на дълбока венозна тромбоза и ТЭЛА при възрастни. (see section 4. 4 for haemodynamically unstable pe patients. Лечение на дълбока венозна тромбоза (dvt) и тромбоэмболии белодробната артерия (ТЭЛА) и за превенция на рецидив на дълбока венозна тромбоза и ТЭЛА при възрастни. (see section 4. 4 за гемодинамически нестабилна ТЭЛА пациенти). adultsprevention of stroke and systemic embolism in adult patients with non valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. Лечение на дълбока венозна тромбоза (dvt) и тромбоэмболии белодробната артерия (ТЭЛА) и за превенция на рецидив на дълбока венозна тромбоза и ТЭЛА при възрастни. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. rivaroxaban accord, co administered with acetylsalicylic acid (asa) alone or with asa plus ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers (see sections 4. 3, 4. 4 и 5. rivaroxaban accord, co administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. adultsprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. Лечение на дълбока венозна тромбоза (dvt) и тромбоэмболии белодробната артерия (ТЭЛА) и за превенция на рецидив на дълбока венозна тромбоза и ТЭЛА при възрастни. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Rivaroxaban Viatris (previously Rivaroxaban Mylan) Kesatuan Eropah - Bulgaria - EMA (European Medicines Agency)

rivaroxaban viatris (previously rivaroxaban mylan)

mylan ireland limited - ривароксабан - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - Антитромботични агенти - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers.  rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events.  ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.  treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult   patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.